| Old Articles: <Older 2971-2980 Newer> |
|---|
 |
BusinessWeek
June 26, 2006
Timothy J. Mullaney |
The Doctor Is (Plugged) In How remote patient monitoring lets fewer specialists provide more attentive care.   |
BusinessWeek
June 26, 2006
Arlene Weintraub |
Homegrown Hormone Therapy: How Safe? Popular alternatives to menopause drugs are under fierce attack by Wyeth and others. |
BusinessWeek
June 26, 2006
Tim Mullaney |
The Sensible Side of Telemedicine Forget sensor shirts that take your vital stats, the cutting edge of e-medicine is in networking and solving labor shortages, but are they good for investors? |
The Motley Fool
June 15, 2006
Brian Gorman |
Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note. |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
Bio-IT World
June 2006
Alan S. Louie |
Semantic Web at the Cusp of Reality Even with successful development of standards and access to the Semantic Web infrastructure, Semantic Web technology overall will not be successful without broad acceptance and adoption by the drug development industry. |
Bio-IT World
June 2006
Mark D. Uehling |
Afferenz on EDC, Images, and Data Integration There are people who think the outsourcing of IT to India will not affect the life sciences. But companies like Afferenz raises concerns about U.S. companies lagging behind Indian companies on laying the foundation for clinical trials. |
The Motley Fool
June 13, 2006
Ryan Fuhrmann |
Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment. |
The Motley Fool
June 13, 2006
Jim Mueller |
Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note. |
Registered Rep.
June 8, 2006
Kristen French |
In Switch, Company Sues NASD For Fraud, Says NASD Aided FBI In Creating Bogus B/D In an unlikely lawsuit, the privately owned cancer research firm Shimoda-Atlantic is suing the NASD for securities fraud. |
| <Older 2971-2980 Newer> Return to current articles. |
